Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 566,278 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $11.22, for a total value of $6,353,639.16. Following the completion of the transaction, the chief operating officer now owns 1,462,223 shares of the company's stock, valued at approximately $16,406,142.06. The trade was a 27.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Eric Venker also recently made the following trade(s):
- On Monday, June 2nd, Eric Venker sold 433,722 shares of Roivant Sciences stock. The shares were sold at an average price of $11.07, for a total value of $4,801,302.54.
- On Tuesday, May 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.95, for a total value of $1,095,000.00.
- On Monday, April 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.22, for a total value of $1,022,000.00.
- On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96.
- On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The stock was sold at an average price of $11.06, for a total value of $3,489,673.32.
Roivant Sciences Trading Up 0.3%
NASDAQ ROIV traded up $0.03 on Friday, reaching $11.23. The stock had a trading volume of 4,927,975 shares, compared to its average volume of 5,573,459. The business has a 50 day moving average price of $10.64 and a 200 day moving average price of $11.01. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The company has a market capitalization of $8.01 billion, a price-to-earnings ratio of -74.86 and a beta of 1.16.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The company had revenue of $7.57 million for the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. During the same quarter last year, the company posted ($0.23) EPS. On average, analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on ROIV shares. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, May 28th.
Get Our Latest Report on Roivant Sciences
Institutional Trading of Roivant Sciences
Several hedge funds have recently added to or reduced their stakes in the business. Inspire Investing LLC bought a new stake in Roivant Sciences during the 1st quarter valued at approximately $303,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company's stock valued at $24,678,000 after acquiring an additional 34,341 shares in the last quarter. Zimmer Partners LP raised its holdings in Roivant Sciences by 111.3% in the 1st quarter. Zimmer Partners LP now owns 534,500 shares of the company's stock valued at $5,393,000 after acquiring an additional 281,600 shares in the last quarter. Clearline Capital LP acquired a new position in Roivant Sciences in the 1st quarter valued at approximately $1,211,000. Finally, Goldman Sachs Group Inc. raised its holdings in Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company's stock valued at $24,553,000 after acquiring an additional 324,764 shares in the last quarter. Institutional investors own 64.76% of the company's stock.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
